Abstract
Purpose To develop a deep learning tool for the automatic segmentation of T2-weighted intramedullary lesions in spinal cord injury (SCI).
Material and Methods This retrospective study included a cohort of SCI patients from three sites enrolled between July 2002 and February 2023. A deep learning model, SCIseg, was trained in a three-phase process involving active learning for the automatic segmentation of intramedullary SCI lesions and the spinal cord. The data consisted of T2-weighted MRI acquired using different scanner manufacturers with heterogeneous image resolutions (isotropic/anisotropic), orientations (axial/sagittal), lesion etiologies (traumatic/ischemic/hemorrhagic) and lesions spread across the cervical, thoracic and lumbar spine. The segmentations from the proposed model were visually and quantitatively compared with other open-source baselines. Wilcoxon signed-rank test was used to compare quantitative MRI biomarkers (lesion volume, lesion length, and maximal axial damage ratio) computed from manual lesion masks and those obtained automatically with SCIseg predictions.
Results MRI data from 191 SCI patients (mean age, 48.1 years ± 17.9 [SD]; 142 males) were used for model training and evaluation. SCIseg achieved the best segmentation performance for both the cord and lesions. There was no statistically significant difference between lesion length and maximal axial damage ratio computed from manually annotated lesions and those obtained using SCIseg.
Conclusion Automatic segmentation of intramedullary lesions commonly seen in SCI replaces the tedious manual annotation process and enables the extraction of relevant lesion morphometrics in large cohorts. The proposed model segments lesions across different etiologies, scanner manufacturers, and heterogeneous image resolutions. SCIseg is open-source and accessible through the Spinal Cord Toolbox.
Summary Automatic segmentation of the spinal cord and T2-weighted lesions in spinal cord injury on MRI scans across different treatment strategies, lesion etiologies, sites, scanner manufacturers, and heterogeneous image resolutions.
Key Results
An open-source, automatic method, SCIseg, was trained and evaluated on a dataset of 191 spinal cord injury patients from three sites for the segmentation of the spinal cord and T2-weighted lesions.
SCIseg generalizes across traumatic and non-traumatic lesions, scanner manufacturers, and heterogeneous image resolutions, enabling the automatic extraction of lesion morphometrics in large multi-site cohorts.
Quantitative MRI biomarkers, namely, lesion length and maximal axial damage ratio derived from the automatic predictions showed no statistically significant difference when compared with manual ground truth, implying reliability in SCIseg’s predictions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Canada Research Chair in Quantitative Magnetic Resonance Imaging [CRC–2020–00179], the Canadian Institute of Health Research [PJT–190258], the Canada Foundation for Innovation [32454, 34824], the Fonds de Recherche du Quebec – Sante [322736, 324636], the Natural Sciences and Engineering Research Council of Canada [RGPIN–2019–07244], the Canada First Research Excellence Fund (IVADO and TransMedTech), the Courtois NeuroMod project, the Quebec BioImaging Network [5886, 35450], INSPIRED (Spinal Research, UK; Wings for Life, Austria; Craig H. Neilsen Foundation, USA), Mila – Tech Transfer Funding Program, the Association Francaise contre les Myopathies (AFM), the Institut pour la Recherche sur la Moelle epiniere et Encephale (IRME), and the Ministry of Health of the Czech Republic, grant nr. NU22–04–00024, the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Development (R03HD094577). ACS is supported by the National Institutes of Health – K01HD106928 and R01NS128478 and the Boettcher Foundation Webb-Waring Biomedical Research Program. KAW is supported by the National Institutes of Health – K23NS104211, L30NS108301, R01NS128478. JV received funding from the European Union's Horizon Europe research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101107932 and is supported by the Ministry of Health of the Czech Republic, grant nr. NU22-04-00024. ENK is supported by the Fonds de Recherche du Quebec Nature and Technologie (FRQNT) Doctoral Training Scholarship and in part by the FRQNT Strategic Clusters Program (2020–RS4–265502 – Centre UNIQUE – Union Neurosciences – Artificial Intelligence – Quebec and in part, by funding from the Canada First Research Excellence Fund through the TransMedTech Institute. The authors thank Digital Research Alliance of Canada for the compute resources used in this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The local ethics committee of the Balgrist University Hospital, Zurich, gave ethical approval for this work. The local ethics committee of the University of Colorado School of Medicine and Craig Hospital, Englewood, Colorado, gave ethical approval for this work. The local ethics committee of the Pitie-Salpetriere Hospital, Paris, gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Figure 1, Table 1 updated to add details on lesion etiologies and injury levels. Added Table 4 showing quantitative metrics for DCM lesions. Added MRI data details in Section 2.2. Overall improvement in clarity of Methods and Discussion.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
